Can a dietary supplement providing natural cGP (cyclic Glycine-Proline) compliment the body’s own internal levels of cGP and help improve the metabolic health of type 2 diabetes sufferers and aid in the recovery of complications associated with metabolic syndrome

An observational study suggested a cause-effect relationship between plasma cGP and clinical manifestations of Type 2 diabetes mellitus (T2DM) and its associated vascular complications. To confirm such relationship, this open label trial is designed to examine the efficacy of natural cGP supplementation on manifestations of T2DM.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN84351085

Enrollment

Registered

2024-07-29

Start date

2021-05-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The efficacy of cGP in vascular complications in patients with diabetes Nutritional, Metabolic, Endocrine

Interventions

To confirm the cause-effect relationship of cyclic glycine-proline (cGP) to manifestations of type 2 diabetes (T2DM), an open-label study is used to examine the efficacy of natural cGP supplementation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female participants aged between 45 and 80 years old 2. More than 8 years of medical history of Type 2 Diabetes Mellitus (T2DM) 3. Current diagnosis of foot diabetic peripheral neuropathy (DPN) 4. Diagnosis of T2DM based on: 4.1. Fasting glucose = 7 mmol/L and/or 4.2. HbA1c = 6.5% 5. Diagnosis of foot DPN based on: 5.1. Self-reporting symptoms 5.2. Foot sensory testing scores 6. Inclusion criteria are independent of: 6.1. Body Mass Index (BMI) 6.2. Blood pressure 6.3. Plasma lipid profiles 6.4. Other complications of T2DM

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Diabetic foot ulcers 3. Any other cause of peripheral neuropathy (drug or injury or Covid-19 associated peripheral neuropathy) 4. Medical history of degenerative neurological conditions 5. History of cognitive impairment 6. Major mental health issues such as: 6.1. Schizophrenia 6.2. Severe depression 6.3. Anxiety

Design outcomes

Primary

Measure	Time frame
Foot sensation measured using Semmes-Weinstein monofilament, vibration and warm/cold perception threshold tests at three hospital visits (Before supplementation, after 3 months of supplementation, and after 6 months of supplementation)	—

Secondary

Measure	Time frame
Measured before supplementation, after 3 months of supplementation, and after 6 months of supplementation: 1. Systolic and diastolic blood pressure measured using a sphygmomanometer at three hospital visits 2. Glucose intolerance measured using fasting blood glucose, HBA1c (%), and triglyceride/glucose index at three hospital visits	—

Countries

China

Contacts

Public ContactJian Guan

jian.guan@thecgplab.com+64 0210366863

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026